# Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Study · id `cardio:ct-nct02932436` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02932436](<https://clinicaltrials.gov/study/NCT02932436>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02932436

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

## Technical summary

Registry record NCT02932436. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-10 (actual); primary completion 2020-06-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 144 participants (enrolled count; ClinicalTrials.gov record NCT02932436, source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)
- Started: 2016-10-10 (actual) (ClinicalTrials.gov record NCT02932436, source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)
- Primary completion: 2020-06-15 (actual) (ClinicalTrials.gov record NCT02932436, source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)
- Completion: 2020-08-31 (actual) (ClinicalTrials.gov record NCT02932436, source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02932436, source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02932436-2021-04-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
- Acronym: EmDia
- Condition: Diabetes Mellitus, Type 2
- Condition: Diastolic Dysfunction
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Johannes Gutenberg University Mainz
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Johannes Gutenberg University Mainz (`cardio:org-johannes-gutenberg-university-mainz`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial (`cardio:pubmed-36763159`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial (`cardio:pubmed-40922034`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2c456aa51df8710cd7abe6d826d9b0393f9c95577ca8358bfa96d5b2fc25c1e0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
